Does the newly added targeted drug in the 2025 medical insurance catalog contain giritinib?

As of2025May month, Gilteritinib (Gilteritinib) has not been included in the latest version of the National Medical Insurance Drug List. According to the "2024<" released by the National Medical Insurance Administration on November 2024 span>National Medical Insurance Drug Catalog", 91 new drugs were added, including 26 cancer drugs, but giritinib was not found. . This means that the cost of giritinib treatment still needs to be borne by the patient, which may pose a certain burden to patients with limited financial conditions.

Currently, giritinib is available on the domestic market, but since it is not included in the medical insurance system, it may be difficult to purchase the drug in hospitals. Patients can purchase the drug through overseas channels. In foreign markets, giritinib has two options: original drug and generic drug. The original drugs mainly include the European version and the Hong Kong version. Among them, the price of the Hong Kong version of giritinib is as high as 100,000 yuan, which is quite expensive. In contrast, the price of the Laotian version of the generic version of giritinib is more affordable, with only more than one thousand to two thousand yuan, which relieves a lot of financial pressure on patients who need the drug, and the ingredients of the original drug and the generic drug are basically the same.

Giritinib is a FLT3 inhibitor, mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3 mutations. Its efficacy has been verified in multiple clinical studies and can significantly extend the progression-free survival of patients. However, due to its high price, many patients cannot afford it in the long term. Therefore, whether giritinib can be included in the medical insurance catalog as soon as possible has become the focus of attention of patients and the medical community.

In the future, as the country attaches great importance to innovative drugs, giritinib is expected to enter the medical insurance catalog through medical insurance negotiations, thus reducing the financial burden on patients. Prior to this, patients should weigh the efficacy and cost of the drug under the guidance of a doctor and choose the treatment plan that best suits them. At the same time, attention can also be paid to the use of generic drugs to reduce the cost of treatment.

Reference materials:https://www.xospata.com/